PEGS Summit Korea
PEGS Korea

Dinner Short Course*

Wednesday, September 21, 6:00pm - 8:30pm



Recombinant antibodies vary widely in their biophysical characteristics, from stable monomers to metastable aggregation-prone oligomers. In particular, antibody variable domains differ in their intrinsic thermodynamic stability and may require labor-intensive engineering. It is therefore essential to implement antibody engineering strategies in screening and initial characterization project phases in order to avoid time and cost consuming optimization strategies in later development. In addition, it is critical to understand how the poor stability of individual variable domains not only limits the biophysical properties of small fragments, but also affects the production yield, stability and homogeneity of full-length IgGs containing these domains.

  • Setup suitable screening campaigns in order to reduce intense engineering efforts
  • Implement stability assessment & engineering strategies early in the discovery phase
  • Combine different engineering strategies to improve desired features and remove liabilities
  • Use sequence or structure-based engineering to optimize your antibody‚Äôs biophysical properties
  • Optimize your choices of the best possible format for your antibody
  • Improve your expression strategies for different immunoglobulin products
  • Tackle the analytical challenges of multi-domain proteins



Jonas SchaeferJonas Schaefer, Ph.D., Head, High-Throughput Binder Selection Facility, Biochemistry, University of Zurich
Julia NeugebauerJulia Neugebauer, Ph.D., Associate Director, Leader Discovery Programs, MorphoSys AG





*Separate registration required.

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  

Register Now

Arrow Right ColDownload 2016 Brochure

2016 PEGS Korea Brochure


Arrow Right ColCorporate Sponsor


Arrow Right ColCorporate Support Sponsors




 Thermo Fisher Scientific

Arrow Right ColSponsoring Organizations

Antibody Society Korea

Arrow Right ColView All Media Partners


Track 1
Protein & Antibody Engineering

Track 2
Cancer Immunotherapy